Chromosome 16q, a Cancer Suppressor Chromosome Arm

16q 染色体，抑癌染色体臂

• 批准号: 344719
• 负责人: Egan Sean E
• 金额: $ 54.02万
• 依托单位: Hospital for Sick Children (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-03-01 至 2021-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=344719&lang=en
• 关键词: Breast Cancer; Cbfb; Cdh1; Chromosome 16q; Chromosome Engineering; Ctcf; E-Cadherin; Lobular Breast Cancer; Pik3ca; Tumor Suppressor; Breast Cancer; Cbfb; Cdh1; Chromosome 16q; Chromosome Engineering; Ctcf; E-Cadherin; Lobular Breast Cancer; Pik3ca; Tumor Suppressor

Patients with estrogen receptor positive (ER+) breast cancer (BC), including those with lobular tumors, show a relatively good prognosis on the five-year horizon. However, unlike triple negative breast cancer (estrogen receptor negative, progesterone rec

雌激素受体阳性（ER+）乳腺癌（BC）的患者（包括小叶肿瘤患者）在五年的视野上表现出相对良好的预后。 但是，与三乳腺癌不同（雌激素受体阴性，孕激素rec）不同